In conclusion, tirzepatide increased blood pressure and sympathetic activity in hypertensive rats without cardiac protection, highlighting context-dependent cardiovascular actions
Until then, GLP-1RA with cardiovascular benefits remains the recommended substance class for obese patients with T2D and pre-existing atherosclerotic vascular disease or patients with a very high risk for this condition (17)
If you're nausea-sensitive, starting with GLP-1s or lower tirzepatide doses makes sense
During 72 weeks of treatment, people taking tirzepatide at doses of 5, 10, or 15 mg lost an average of 15.0%, 19.5%, and 20.9%, respectively, compared with just 3.1% in people taking a placebo
Aim to prioritize protein to help increase GLP-1 and shift eating habits